| 4.73 0.5 (11.82%) | 03-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.52 |
1-year : | 6.45 |
| Resists | First : | 4.73 |
Second : | 5.52 |
| Pivot price | 4.09 |
|||
| Supports | First : | 3.98 |
Second : | 3.51 |
| MAs | MA(5) : | 4.18 |
MA(20) : | 4.03 |
| MA(100) : | 3.12 |
MA(250) : | 1.94 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 57.7 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 4.88 | Low : | 0.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STTK ] has closed Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.74 - 4.76 | 4.76 - 4.78 |
| Low: | 4.19 - 4.21 | 4.21 - 4.22 |
| Close: | 4.7 - 4.73 | 4.73 - 4.77 |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Wed, 25 Feb 2026
Shattuck Labs Announces Participation in Upcoming March Investor Conferences - Investing News Network
Sun, 22 Feb 2026
STTK - Shattuck Labs, Inc. Latest Stock News & Market Updates - Stock Titan
Thu, 12 Feb 2026
Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Fri, 06 Feb 2026
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium - Investing News Network
Fri, 06 Feb 2026
Shattuck Labs Sets Earlier Date for 2026 Annual Meeting - The Globe and Mail
Fri, 06 Feb 2026
Shattuck Labs Insider Buyers Net US$637k Despite 12% Stock Decline - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 3.794e+007 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 1,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.383e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 71.5 % |
| Return on Equity (ttm) | -34 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | -42.7 |
| Sales Per Share | -37.08 |
| EBITDA (p.s.) | 1.39103e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.13 |
| Price to Cash Flow | 4.98 |
| Dividend | 0 |
| Forward Dividend | 2.25e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|